Twist Bioscience Corp (NASDAQ: TWST)’s stock price has plunge by 28.74relation to previous closing price of 32.01. Nevertheless, the company has seen a 30.66% surge in its stock price over the last five trading sessions. Seeking Alpha reported 2024-05-02 that Twist Bioscience Corporation (NASDAQ:TWST ) Q2 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Angela Bitting – Senior Vice President, Corporate Affairs Emily Leproust – Chief Executive Officer & Co-Founder Adam Laponis – Chief Financial Officer Conference Call Participants Matt Sykes – Goldman Sachs Vijay Kumar – Evercore ISI Steven Mah – Cowen Tom Peterson – Baird Operator Welcome to Twist Bioscience’s Fiscal 2024 Second Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode.
Is It Worth Investing in Twist Bioscience Corp (NASDAQ: TWST) Right Now?
Additionally, the 36-month beta value for TWST is 1.73. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for TWST is 55.69M and currently, short sellers hold a 22.00% ratio of that float. The average trading volume of TWST on May 06, 2024 was 875.59K shares.
TWST’s Market Performance
The stock of Twist Bioscience Corp (TWST) has seen a 30.66% increase in the past week, with a 28.86% rise in the past month, and a 12.63% gain in the past quarter. The volatility ratio for the week is 8.91%, and the volatility levels for the past 30 days are at 5.88% for TWST. The simple moving average for the past 20 days is 33.19% for TWST’s stock, with a 48.38% simple moving average for the past 200 days.
Analysts’ Opinion of TWST
Many brokerage firms have already submitted their reports for TWST stocks, with Goldman repeating the rating for TWST by listing it as a “Buy.” The predicted price for TWST in the upcoming period, according to Goldman is $45 based on the research report published on January 17, 2024 of the current year 2024.
Berenberg, on the other hand, stated in their research note that they expect to see TWST reach a price target of $27. The rating they have provided for TWST stocks is “Buy” according to the report published on September 27th, 2023.
Scotiabank gave a rating of “Sector Outperform” to TWST, setting the target price at $33 in the report published on January 05th of the previous year.
TWST Trading at 21.01% from the 50-Day Moving Average
After a stumble in the market that brought TWST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.63% of loss for the given period.
Volatility was left at 5.88%, however, over the last 30 days, the volatility rate increased by 8.91%, as shares surge +26.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.71% upper at present.
During the last 5 trading sessions, TWST rose by +30.66%, which changed the moving average for the period of 200-days by +58.44% in comparison to the 20-day moving average, which settled at $31.37. In addition, Twist Bioscience Corp saw 11.80% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TWST starting from Finn Patrick John, who sale 2,174 shares at the price of $30.12 back on Apr 23 ’24. After this action, Finn Patrick John now owns 176,206 shares of Twist Bioscience Corp, valued at $65,483 using the latest closing price.
Laponis Adam, the Chief Financial Officer of Twist Bioscience Corp, sale 556 shares at $33.16 during a trade that took place back on Apr 09 ’24, which means that Laponis Adam is holding 74,444 shares at $18,434 based on the most recent closing price.
Stock Fundamentals for TWST
Current profitability levels for the company are sitting at:
- -0.84 for the present operating margin
- 0.36 for the gross margin
The net margin for Twist Bioscience Corp stands at -0.78. The total capital return value is set at -0.33. Equity return is now at value -30.40, with -24.68 for asset returns.
Based on Twist Bioscience Corp (TWST), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -1.21. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is -55175.5.
Currently, EBITDA for the company is -193.21 million with net debt to EBITDA at 0.96. When we switch over and look at the enterprise to sales, we see a ratio of 8.3. The receivables turnover for the company is 7.42for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.51.
Conclusion
In conclusion, Twist Bioscience Corp (TWST) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
